



<p>Subpart B for Form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	Wolfgang Doering et al. 10595067
				Filing Date	January 27, 2006
				First Named Inventor	WOLFGANG DÖRING ET AL.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket Number	WAS 0757 PUSA

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Mark Berch/ (04/25/2008)	Date Considered	
-----------------------	---------------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Substitute for Form 1449B/PTO				Complete if Known	
				Application Number	10/595,067
				Filing Date	January 27, 2006
				First Named Inventor	WOLFGANG DÖRING ET AL.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	WAS 0757 PUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kim et al., "1,3-Dioxolanylpurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes," J. MED. CHEM., Vol. 36, 1993, pp. 30-37	
		Evans et al., "Divergent Asymmetric Syntheses of Dioxolane Nucleoside Analogues," TETRAHEDRON: ASYMMETRY, Vol. 4, No. 11, 1993, pp. 2319-2322	
		Kim et al., "L-β-(2S,4S)- and L-α-(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships," JOURNAL OF MEDICINAL CHEMISTRY, Vol. 36, No. 5, March 1993, pp. 519-528	
		Vobrüggen et al., "On the Mechanism of Nucleoside Synthesis," CHEM. BER. 114, 1981, pp. 1256-1268	
		March et al., "Advanced Organic Chemistry," Wiley & Sons, Inc., 3 rd Edition, p. 179 and pp. 310-317 1985	
		Greene et al., "Protection for the Hydroxyl Group Including 1,2- and 1,3-Diols," PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, Inc., 2 nd Edition, pp. 10-117 1991	
		"Protection for the Amino Group," PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, Inc., 2 nd Edition, pp. 309-385 (Greene et al., 1991)	

Examiner Signature	/Mark Berch/ (04/25/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/